Summary | A federal appeals court ruled that Actavis cannot
pull an older Alzheimer's drug from the market in order to
switch patients to a newer, more expensive version before
generic competition emerged.
pull an older Alzheimer's drug from the market in order to
switch patients to a newer, more expensive version before
generic competition emerged.
blogs.wsj.com | 22 May 2015